type KRAS

Related by string. * Types . types . TYPES . TYPE . Type : BULLETIN TYPE Private Placement . BULLETIN TYPE Halt BULLETIN . BULLETIN TYPE Resume Trading . PCT MATURITY #/#/# TYPE [002] . Exercise Type . Acura TL Type / Kras . Kra . K RAS . K ras . KRAs : mutated KRAS . non mutated KRAS . KRAS gene mutations . KRAS gene mutation . KRAS BRAF . KRAS oncogene * type KRAS mCRC . type KRAS tumors *

Related by context. Frequent words. (Click for all words.) 70 K ras 63 K RAS 60 mCRC 60 FLT3 58 KRAS mutations 56 EGFR mutations 56 JAK2 56 metastatic renal cell carcinoma 56 heavily pretreated 55 factor receptor EGFR 54 interferon alfa 54 KRAS 54 FOLFIRI 54 cetuximab 54 heterozygous 53 EGFR expressing metastatic colorectal 53 overexpressing 53 homozygous 53 indolent NHL 53 metastatic colorectal cancer 53 chronic lymphocytic leukemia CLL 53 plus dexamethasone 53 fludarabine 52 androgen independent 52 panitumumab 52 EGFR 52 pheochromocytoma 52 bucindolol 52 Vectibix 52 evaluable 52 superficial bladder cancer 52 chronic myeloid leukemia CML 51 breast carcinoma 51 BCR ABL 51 mammary tumors 51 HCV infected 51 sunitinib 51 Laquinimod 51 HER2/neu 51 plus gemcitabine 51 free survival PFS 51 medullary thyroid cancer 51 Torisel 51 Amrubicin 51 pegylated 51 azacitidine 51 overexpress 51 orphan medicinal product 51 liver metastases 51 Everolimus 51 NSCLC 51 vandetanib 51 FOLFOX 50 HER2 positive metastatic breast 50 BRAF mutation 50 decitabine 50 estrogen receptor ER 50 Chronic Hepatitis C 50 Lenalidomide 50 survivin 50 allogeneic stem cell 50 etoposide 50 unresectable 50 HCV genotype 1 50 Alemtuzumab 50 genotypic 50 violent propensities 50 imatinib 50 HSCT 50 relapsed refractory 50 hypercalcemia 50 gastrointestinal stromal tumors 50 neoadjuvant chemotherapy 50 metastatic melanoma 50 myeloid 50 Secondary endpoints included 50 HGS ETR1 50 xenograft models 50 IV melanoma 50 CMV disease 50 induced apoptosis 50 transfected 49 mice lacking 49 advanced NSCLC 49 diagnosed multiple myeloma 49 metastatic hormone refractory 49 romiplostim 49 erlotinib 49 nitazoxanide 49 distant metastasis 49 CYP#C# [002] 49 luteinizing hormone releasing 49 plus prednisone 49 Secondary endpoints include 49 refractory multiple myeloma 49 B CLL 49 hematopoietic cell 49 tumor lysis syndrome 49 hypoxia inducible factor 49 complete remissions 49 Cethromycin

Back to home page